Dan Mandell

𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: George Church on the key innovations in synthetic biology that are poised to make contributions to biotechnology over the coming years. With @gro_bio's @dj_mandell. Full video: biotechtv.com/post/george-ch…

𝐓𝐡𝐞 𝐒𝐭𝐮𝐝𝐢𝐨 𝐚𝐭 𝐊𝐞𝐧𝐝𝐚𝐥𝐥 𝐒𝐪𝐮𝐚𝐫𝐞: George Church on computer augmentation of the brain and making progress on diseases of aging. With @gro_bio's @dj_mandell. Full video: biotechtv.com/post/george-ch…

Had a blast sitting down with my @gro_bio co-founder and Scientific Advisory Board Chair @geochurch to discuss genomically recoded organisms, principles of founder-led bio, the near-term impact of synthetic biology on biotechnology, planetary colonization, brain mapping, and more. Many thanks to @bradloncar and @BiotechTVHQ for having us! biotechtv.com/post/george-ch…

Honored to have George Church in the podcast studio today. This episode will air on Tuesday. 30+ minutes of his take on the latest in science, startups, and the future. Interviewed by @dj_mandell.

So proud of this team – we had a terrifically fun day keeping it (sur)real!

A key limitation of protein drugs: The body sees them as foreign, triggering an immune response to the protein. @gro_bio engineers proteins to avoid immune responses. The #startup now has $60m in Series B cash to show it can challenge a drug from @Amgen. medcitynews.com/2024/07/gout-a…

I am thrilled to announce @gro_bio's $60.3M Series B financing, co-led by @atlasventure and Access Biotechnology! This financing is the culmination of an enormous body of work by our entire company, including our GRO platform, product pipeline, and business development personnel, and I could not be more proud of our team. GRObio has presented impressive pre-clinical data across multiple disease indications, and this financing will power the acquisition of efficacy data in clinical trials for our lead program in chronic refractory gout. It will further advance and broaden our pipeline, as well as enable next-gen approaches to drugs like ADCs through the simultaneous attachment of distinct payloads through multiple non-standard amino acids. I'm excited to partner with @KevinBitterman, Dan Becker, @jernejgodec and Christine Borowski, who are reuniting via GRObio after previous successful co-investments, including Mariana Oncology and their recent acquisition by Novartis. With this financing, together with the continued participation of our Series A investors including @LeapsByBayer, Redmile Group, @digitalisvc, and @iendeavors, we have assembled the ideal syndicate to advance GRObio to a clinical-stage company. Our team is eager to begin this new chapter, and to rise to meet its attendant challenges. And most importantly, we are grateful for the opportunity to bring our therapies to the patients who need them. Many thanks to @hannah_reports at @BosBizJournal, @bradloncar at @BiotechTVHQ, and @RLCscienceboss at @endpts, for excellent early coverage of our financing. Press release: businesswire.com/news/home/2024… Boston Business Journal: #cxrecs_s" target="_blank" rel="nofollow noopener">bizjournals.com/boston/news/20… Biotech TV: Biotech TV: biotechtv.com/post/gro-biosc… Endpoints: endpts.com/gro-bioscience… On we GRO!

What's on the horizon for new engineered protein and nucleic acid therapeutics, like #tRNA? This panel on May 7th at 1:45pm PT at #SynBioBeta2024 featuring Alltrna, @SPOCbio, @gro_bio & NextRNA will explore this topic and more. See more at @SynBioBeta: web.cvent.com/event/7ff628c3…

@gro_bio had a great time connecting with inspiring immune tolerance colleagues at ASITS2024!

Many thanks to @edsilverman at @statnews for featuring @gro_bio's hiring of Tracey Lodie as Chief Development Officer to drive our assets through clinical development! statnews.com/pharmalot/2024…

I'm excited to announce the addition of Tracey Lodie to our executive team as Chief Development Officer! Her world-class background in translational immunology brings the perfect complement to @gro_bio as we advance our ProGly™ assets to the clinic. tinyurl.com/bdxj723m

@gro_bio is excited to present at SynBioBeta this year together with these other leaders building the bridge between synthetic biology and game changing therapeutics!

Great perspective from @iendeavors's Joel Dudley on achieving balance between platforms and pipelines, and the importance of focusing new technologies on increasing translatability over discovery endpts.com/innovation-end…

We're thrilled to officially partner with @LS_Cares, a fantastic organization dedicated to bringing opportunities in life sciences to all people. Please check them out and consider joining one of the many give-back opportunities they offer!

I had a blast speaking with Chris O'Brien! Check out the latest episode of Few & Far Between to learn about reprogramming the genetic code, AI's future in protein design, and how the convergence of these technologies grants us access to precise control of the immune system.

@rowanwalrath Only one thing to be done

Honey has spilled inside my backpack. Is there anything to be done?

So proud of our team at @gro_bio for rapidly delivering positive animal data on two novel therapeutic mechanisms! Treating autoimmune disease without immunosuppression and preventing immunogenicity to drugs are two of the most pressing needs for effective therapies for patients.

I had a great time speaking with @TarasavaKatia about 3 of my favorite topics: Jurassic Park, new genetic codes, and the power of non-standard amino acids. Check out Katia’s @protolifemedia article to learn how @gro_bio uses GROs to reverse autoimmunity and immunogenicity!

I’ve been a big fan of @bradloncar's content for years. It was a great pleasure to host him and @BiotechTVHQ at @gro_bio's HQ in Kendall Sq, Cambridge to discuss how computational design and automation are enabling our GRO platform to revolutionize protein and gene therapies!

Thanks to @HGlorikian for bringing me on your show! We explored the therapeutic frontiers we’re reaching with new amino acids in our unique GRO platform, and dissected the hype and promise of the impact generative AI will have on drug discovery.